ADHD Drug Safety Evaluation Could Start With Short Cardiac Function Studies
Executive Summary
Members of FDA's Drug Safety & Risk Management Advisory Committee are proposing short-term studies of cardiac function as a feasible method to evaluate cardiovascular risks associated with attention deficit/hyperactivity disorder drugs
You may also be interested in...
Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling
Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval
Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling
Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval
ADHD Drug Cardiovascular Risk Should Be Extended to Strattera, Cmte. Says
Warnings about cardiovascular risk associated with pediatric use of attention deficit/hyperactivity disorder treatments should be extended to Lilly's Strattera, FDA's Pediatric Advisory Committee recommended